{"id":692353,"date":"2022-10-05T08:29:08","date_gmt":"2022-10-05T12:29:08","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/nextcure-to-give-two-presentations-at-society-for-immunotherapy-of-cancer-annual-meeting\/"},"modified":"2022-10-05T08:29:08","modified_gmt":"2022-10-05T12:29:08","slug":"nextcure-to-give-two-presentations-at-society-for-immunotherapy-of-cancer-annual-meeting","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/nextcure-to-give-two-presentations-at-society-for-immunotherapy-of-cancer-annual-meeting\/","title":{"rendered":"NextCure to Give Two Presentations at Society for Immunotherapy of Cancer  Annual Meeting"},"content":{"rendered":"<div class=\"mw_release\">\n<p>BELTSVILLE, Md., Oct.  05, 2022  (GLOBE NEWSWIRE) &#8212; <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=EvTzXHqEq57TxQMB7D0kHE4Ft1OQ1ABFCNtD1DuTdR-IP0MezZq1JiqySq5JWmyjguN85CYKs5k_UA_EKzZ6kg==\" rel=\"nofollow noopener\" target=\"_blank\">NextCure, Inc.<\/a>\u00a0(Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced two presentations at the Society for Immunotherapy of Cancer (SITC) annual meeting, to be held in Boston in November 8-12, 2022. NextCure will share new data from its Phase 1 clinical study of NC762 and a high level overview of its ongoing NC410 combination study during poster sessions.<\/p>\n<p>\n        <strong>Poster Presentation Details:<\/strong>\n      <\/p>\n<p>\n        <strong>Title<\/strong>: 1. A phase 1\/2, open-label, dose-escalation, safety and tolerability study of NC762 in subjects with advanced or metastatic solid tumors<br \/><strong>Lead Author<\/strong>: Satish Shah<br \/><strong>Abstract Number<\/strong>: 748<br \/><strong>Session Date &amp; Time<\/strong>: Friday, November 11, 2022, 7:00-8:30 PM<\/p>\n<p><strong>Title<\/strong>: 4. A Phase 1b\/2, open-label, safety, tolerability and efficacy study of NC410 plus pembrolizumab for participants with immune checkpoint inhibitor (ICI) refractory or MSS\/MSI-low ICI na\u00efve advanced or metastatic solid tumors<br \/><strong>Lead Author<\/strong>: Eric Christenson<br \/><strong>Abstract Number<\/strong>: 739<br \/><strong>Session Date &amp; Time<\/strong>: Thursday November 10, 2022: 7:30-9:00 PM<\/p>\n<p>\n        <strong>About NC762<\/strong><br \/>\n        <br \/>NC762 is a monoclonal antibody targeting B7-H4, a protein expressed on multiple tumor types. We believe NC762 acts by inhibiting tumor cell growth and killing tumor cells, including by enhancing immune response. In preclinical studies, NC762 inhibits the growth of human melanoma tumors in mice and inhibits tumor cell growth independently of immune cell infiltration in the tumor microenvironment. We believe that NC762 has the potential to treat multiple tumor types.<\/p>\n<p>\n        <strong>About NC410<\/strong><br \/>\n        <br \/>NC410 is a first-in-class immunomedicine designed to block immune suppression mediated by LAIR-1, an immunomodulatory receptor expressed on T cells and myeloid cells, including dendritic cells, a type of antigen presenting cell. In preclinical research, it has been shown that LAIR-1 inhibits T cell function and myeloid activity. In preclinical studies, NC410 blocks the negative effects of LAIR-1 and promotes T cell function and myeloid cell activity.\u00a0NextCure\u00a0believes NC410 has the potential to treat multiple cancer types.<\/p>\n<p>\n        <strong>About\u00a0NextCure, Inc.<\/strong><br \/>\n        <br \/>NextCure\u00a0is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases. Through our proprietary FIND-IO\u2122 platform, we study various immune cells to discover and understand targets and structural components of immune cells and their functional impact in order to develop immunomedicines. Our initial focus is to bring hope and new treatments to patients who do not respond to current cancer therapies, patients whose cancer progresses despite treatment and patients with cancer types not adequately addressed by available therapies.\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=ahMgSDasPGw4mzvV1SQk1AJZnjTWRCGmgwLKOeoEVe0F4TuvT2sHXn_esuL-BSe1m_2bOdLhsR-OnMvdd1fvc7_7Iqm1uhQuj3HPp7r3lmM=\" rel=\"nofollow noopener\" target=\"_blank\">http:\/\/www.nextcure.com<\/a><\/p>\n<p>\n        <strong>Cautionary Statement Regarding Forward-Looking Statements<\/strong><br \/>\n        <br \/>Statements made in this press release that are not historical facts are forward-looking statements. Words such as \u201cexpects,\u201d \u201cbelieves,\u201d \u201cintends,\u201d \u201chope,\u201d \u201cforward\u201d and similar expressions are intended to identify forward-looking statements. Examples of forward-looking statements in this press release include, among others, statements about NextCure\u2019s plans, objectives and intentions with respect to the discovery of immunomedicine targets and the discovery and development of immunomedicines. Forward-looking statements involve substantial risks and uncertainties that could cause actual results to differ materially from those projected in any forward-looking statement. Such risks and uncertainties include, among others: our limited operating history and no products approved for commercial sale; our history of significant losses; our need to obtain additional financing; risks related to clinical development, marketing approval and commercialization; and the unproven approach to the discovery and development of product candidates based on our FIND-IO platform. More detailed information on these and additional factors that could affect NextCure\u2019s actual results are described in NextCure\u2019s filings with the\u00a0Securities and Exchange Commission\u00a0(the \u201cSEC\u201d), including NextCure\u2019s most recent Form 10-K and subsequent Form 10-Q. You\u00a0should not place undue reliance on any forward-looking statements.\u00a0NextCure\u00a0assumes no obligation to update any forward-looking statements, even if expectations change.<\/p>\n<p>\n        <strong>Investor Inquiries<\/strong><br \/>\n        <br \/>Timothy Mayer, Ph.D.<br \/>NextCure, Inc.<br \/>Chief Operating Officer<br \/>(240) 762-6486<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=OUC9sy-3aLtc51K5BncA32tkeDbDDxqqtwp1CtLrEJe8zFnDbXr25_cOclgt68eD4pGfjRZFZoquTvSXHgzxgg==\" rel=\"nofollow noopener\" target=\"_blank\">IR@nextcure.com<\/a><\/p>\n<p>      <img decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY1OTA5MSM1MTg3NTgxIzIxMjU4MzY=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" src=\"https:\/\/ml.globenewswire.com\/media\/OTk4NjRjYmUtZWQ3Yi00MzNhLTg0NGUtNGYwMmM3NDMzODRjLTExMzc0MDc=\/tiny\/NextCure.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>BELTSVILLE, Md., Oct. 05, 2022 (GLOBE NEWSWIRE) &#8212; NextCure, Inc.\u00a0(Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced two presentations at the Society for Immunotherapy of Cancer (SITC) annual meeting, to be held in Boston in November 8-12, 2022. NextCure will share new data from its Phase 1 clinical study of NC762 and a high level overview of its ongoing NC410 combination study during poster sessions. Poster Presentation Details: Title: 1. A phase 1\/2, open-label, dose-escalation, safety and tolerability study of NC762 in subjects with advanced or metastatic solid tumorsLead Author: Satish ShahAbstract Number: 748Session Date &amp; Time: Friday, November 11, 2022, 7:00-8:30 PM Title: 4. &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/nextcure-to-give-two-presentations-at-society-for-immunotherapy-of-cancer-annual-meeting\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;NextCure to Give Two Presentations at Society for Immunotherapy of Cancer  Annual Meeting&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-692353","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.1 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>NextCure to Give Two Presentations at Society for Immunotherapy of Cancer Annual Meeting - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/nextcure-to-give-two-presentations-at-society-for-immunotherapy-of-cancer-annual-meeting\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"NextCure to Give Two Presentations at Society for Immunotherapy of Cancer Annual Meeting - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"BELTSVILLE, Md., Oct. 05, 2022 (GLOBE NEWSWIRE) &#8212; NextCure, Inc.\u00a0(Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced two presentations at the Society for Immunotherapy of Cancer (SITC) annual meeting, to be held in Boston in November 8-12, 2022. NextCure will share new data from its Phase 1 clinical study of NC762 and a high level overview of its ongoing NC410 combination study during poster sessions. Poster Presentation Details: Title: 1. A phase 1\/2, open-label, dose-escalation, safety and tolerability study of NC762 in subjects with advanced or metastatic solid tumorsLead Author: Satish ShahAbstract Number: 748Session Date &amp; Time: Friday, November 11, 2022, 7:00-8:30 PM Title: 4. &hellip; Continue reading &quot;NextCure to Give Two Presentations at Society for Immunotherapy of Cancer Annual Meeting&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/nextcure-to-give-two-presentations-at-society-for-immunotherapy-of-cancer-annual-meeting\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2022-10-05T12:29:08+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY1OTA5MSM1MTg3NTgxIzIxMjU4MzY=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nextcure-to-give-two-presentations-at-society-for-immunotherapy-of-cancer-annual-meeting\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nextcure-to-give-two-presentations-at-society-for-immunotherapy-of-cancer-annual-meeting\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"NextCure to Give Two Presentations at Society for Immunotherapy of Cancer Annual Meeting\",\"datePublished\":\"2022-10-05T12:29:08+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nextcure-to-give-two-presentations-at-society-for-immunotherapy-of-cancer-annual-meeting\\\/\"},\"wordCount\":647,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nextcure-to-give-two-presentations-at-society-for-immunotherapy-of-cancer-annual-meeting\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODY1OTA5MSM1MTg3NTgxIzIxMjU4MzY=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nextcure-to-give-two-presentations-at-society-for-immunotherapy-of-cancer-annual-meeting\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nextcure-to-give-two-presentations-at-society-for-immunotherapy-of-cancer-annual-meeting\\\/\",\"name\":\"NextCure to Give Two Presentations at Society for Immunotherapy of Cancer Annual Meeting - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nextcure-to-give-two-presentations-at-society-for-immunotherapy-of-cancer-annual-meeting\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nextcure-to-give-two-presentations-at-society-for-immunotherapy-of-cancer-annual-meeting\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODY1OTA5MSM1MTg3NTgxIzIxMjU4MzY=\",\"datePublished\":\"2022-10-05T12:29:08+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nextcure-to-give-two-presentations-at-society-for-immunotherapy-of-cancer-annual-meeting\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nextcure-to-give-two-presentations-at-society-for-immunotherapy-of-cancer-annual-meeting\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nextcure-to-give-two-presentations-at-society-for-immunotherapy-of-cancer-annual-meeting\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODY1OTA5MSM1MTg3NTgxIzIxMjU4MzY=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODY1OTA5MSM1MTg3NTgxIzIxMjU4MzY=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nextcure-to-give-two-presentations-at-society-for-immunotherapy-of-cancer-annual-meeting\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"NextCure to Give Two Presentations at Society for Immunotherapy of Cancer Annual Meeting\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"NextCure to Give Two Presentations at Society for Immunotherapy of Cancer Annual Meeting - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/nextcure-to-give-two-presentations-at-society-for-immunotherapy-of-cancer-annual-meeting\/","og_locale":"en_US","og_type":"article","og_title":"NextCure to Give Two Presentations at Society for Immunotherapy of Cancer Annual Meeting - Market Newsdesk","og_description":"BELTSVILLE, Md., Oct. 05, 2022 (GLOBE NEWSWIRE) &#8212; NextCure, Inc.\u00a0(Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced two presentations at the Society for Immunotherapy of Cancer (SITC) annual meeting, to be held in Boston in November 8-12, 2022. NextCure will share new data from its Phase 1 clinical study of NC762 and a high level overview of its ongoing NC410 combination study during poster sessions. Poster Presentation Details: Title: 1. A phase 1\/2, open-label, dose-escalation, safety and tolerability study of NC762 in subjects with advanced or metastatic solid tumorsLead Author: Satish ShahAbstract Number: 748Session Date &amp; Time: Friday, November 11, 2022, 7:00-8:30 PM Title: 4. &hellip; Continue reading \"NextCure to Give Two Presentations at Society for Immunotherapy of Cancer Annual Meeting\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/nextcure-to-give-two-presentations-at-society-for-immunotherapy-of-cancer-annual-meeting\/","og_site_name":"Market Newsdesk","article_published_time":"2022-10-05T12:29:08+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY1OTA5MSM1MTg3NTgxIzIxMjU4MzY=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nextcure-to-give-two-presentations-at-society-for-immunotherapy-of-cancer-annual-meeting\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nextcure-to-give-two-presentations-at-society-for-immunotherapy-of-cancer-annual-meeting\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"NextCure to Give Two Presentations at Society for Immunotherapy of Cancer Annual Meeting","datePublished":"2022-10-05T12:29:08+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nextcure-to-give-two-presentations-at-society-for-immunotherapy-of-cancer-annual-meeting\/"},"wordCount":647,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nextcure-to-give-two-presentations-at-society-for-immunotherapy-of-cancer-annual-meeting\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY1OTA5MSM1MTg3NTgxIzIxMjU4MzY=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nextcure-to-give-two-presentations-at-society-for-immunotherapy-of-cancer-annual-meeting\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/nextcure-to-give-two-presentations-at-society-for-immunotherapy-of-cancer-annual-meeting\/","name":"NextCure to Give Two Presentations at Society for Immunotherapy of Cancer Annual Meeting - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nextcure-to-give-two-presentations-at-society-for-immunotherapy-of-cancer-annual-meeting\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nextcure-to-give-two-presentations-at-society-for-immunotherapy-of-cancer-annual-meeting\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY1OTA5MSM1MTg3NTgxIzIxMjU4MzY=","datePublished":"2022-10-05T12:29:08+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nextcure-to-give-two-presentations-at-society-for-immunotherapy-of-cancer-annual-meeting\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/nextcure-to-give-two-presentations-at-society-for-immunotherapy-of-cancer-annual-meeting\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nextcure-to-give-two-presentations-at-society-for-immunotherapy-of-cancer-annual-meeting\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY1OTA5MSM1MTg3NTgxIzIxMjU4MzY=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY1OTA5MSM1MTg3NTgxIzIxMjU4MzY="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nextcure-to-give-two-presentations-at-society-for-immunotherapy-of-cancer-annual-meeting\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"NextCure to Give Two Presentations at Society for Immunotherapy of Cancer Annual Meeting"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/692353","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=692353"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/692353\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=692353"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=692353"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=692353"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}